Le Treut Y P, Delpero J R, Dousset B, Cherqui D, Segol P, Mantion G, Hannoun L, Benhamou G, Launois B, Boillot O, Domergue J, Bismuth H
Department of Surgery, Hopital de La Conception, Marseilles, France.
Ann Surg. 1997 Apr;225(4):355-64. doi: 10.1097/00000658-199704000-00003.
The purpose of this study was to assess the value and timing of orthotopic liver transplantation (OLT) in the treatment of metastatic neuroendocrine tumors (NET).
Liver metastasis from NET seems less invasive than other secondary tumors. This observation suggests that OLT may be indicated when other therapies become ineffective. However, the potential benefit of this highly aggressive procedure is difficult to assess due to the scarcity and heterogeneity of NET.
A retrospective multicentric study was carried out, including all cases of OLT for NET performed in France between 1989 and 1994. There were 15 cases of metastatic carcinoid tumor and 16 cases of islet cell carcinomas. Hormone-related symptoms were present in 16 cases (55%). Only 5 patients (16%) had no previous surgical or medical therapy before OLT. Median delay from diagnosis of liver metastasis and OLT was 19 months (range, 2 to 120).
The primary tumor was removed at the time of OLT in 11 cases, by upper abdominal exenteration in 7 cases and the Whipple resection in 3. Actuarial survival rate after OLT was 59% at 1 year, 47% at 3 years, and 36% at 5 years. Survival rates were significantly higher for metastatic carcinoid tumors (69% at 5 years) than for noncarcinoid apudomas (8% at 4 years), because of higher tumor- and non-tumor-related mortality rates for the latter.
OLT can achieve control of hormonal symptoms and prolong survival in selected patients with liver metastasis of carcinoid tumors. It does not seem indicated for other NET.
本研究旨在评估原位肝移植(OLT)治疗转移性神经内分泌肿瘤(NET)的价值及时机。
NET的肝转移似乎比其他继发性肿瘤侵袭性小。这一观察结果提示,当其他治疗无效时,可能需要进行OLT。然而,由于NET病例稀缺且具有异质性,这种高侵袭性手术的潜在益处难以评估。
开展一项回顾性多中心研究,纳入1989年至1994年间在法国进行的所有OLT治疗NET的病例。其中有15例转移性类癌肿瘤和16例胰岛细胞瘤。16例(55%)出现激素相关症状。OLT前仅有5例患者(16%)未接受过手术或药物治疗。从诊断肝转移到进行OLT的中位间隔时间为19个月(范围2至120个月)。
11例在OLT时切除了原发肿瘤,7例通过上腹部脏器清除术,3例通过惠普尔切除术。OLT后的精算生存率1年时为59%,3年时为47%,5年时为36%。转移性类癌肿瘤的生存率(5年时为69%)显著高于非类癌性APUD瘤(4年时为8%),因为后者的肿瘤及非肿瘤相关死亡率更高。
OLT可控制类癌肿瘤肝转移患者的激素症状并延长生存期。对于其他NET似乎并无必要。